This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street

Core Insights - Viking Therapeutics, Inc. is recognized as a strong buy by Wall Street analysts, with a reaffirmed Buy rating and a price target of $102 following successful enrollment in its Phase 3 VANQUISH-1 obesity study, exceeding the target with 4,650 participants [1][2] Group 1: Clinical Trials and Pipeline Development - The VANQUISH-2 study is currently enrolling 1,100 adults with type 2 diabetes who are also obese or overweight, expected to complete enrollment by early 2026, focusing on weekly injections of VK2735 [2] - Viking Therapeutics is advancing its obesity treatment VK2735 into Phase III trials after Phase II results indicated up to 12.2% weight loss [3] - The company is also progressing its Amylin agonist program into clinical trials, with plans to file an IND next year [4] Group 2: Financial Position - Viking Therapeutics ended the third quarter with $700 million in cash reserves, which is deemed sufficient to accelerate pipeline development [4] Group 3: Company Overview - Viking Therapeutics is a clinical-stage biopharma company focused on developing treatments for metabolic and endocrine diseases, including obesity and fatty liver, primarily utilizing small-molecule drugs targeting hormone receptors [5]